EMMA

Healthcare Biotechnology

Emmaus Life Sciences, Inc.

$0.04

-0.02 -35.08% today

Price History

Not enough data

Key Stats

Market Cap

2.96M

Avg Volume

123,557

EPS

-$0.10

52W High

$0.09

52W Low

$0.01

Div. Yield

0.0%

Valuation

Forward P/E

-0.60

P/B Ratio

-0.04

P/S Ratio

0.19

EV/EBITDA

6.66

EV/Revenue

1.98

Margins

Gross Margin 93.6%

Operating Margin 60.0%

Net Margin (38.8%)

EBITDA Margin 29.7%

Growth & Returns

Revenue Growth (YoY)

124.3%

Return on Assets

14.3%

Liquidity & Leverage

Current Ratio

0.09

Quick Ratio

0.05

Total Cash

2.81M

Total Debt

30.52M

About

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.